MX2024005430A - Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau. - Google Patents
Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau.Info
- Publication number
- MX2024005430A MX2024005430A MX2024005430A MX2024005430A MX2024005430A MX 2024005430 A MX2024005430 A MX 2024005430A MX 2024005430 A MX2024005430 A MX 2024005430A MX 2024005430 A MX2024005430 A MX 2024005430A MX 2024005430 A MX2024005430 A MX 2024005430A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- dosage forms
- antibody compositions
- tau antibody
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163275045P | 2021-11-03 | 2021-11-03 | |
| US202163290278P | 2021-12-16 | 2021-12-16 | |
| US202263316582P | 2022-03-04 | 2022-03-04 | |
| US202263316616P | 2022-03-04 | 2022-03-04 | |
| PCT/IB2022/060604 WO2023079485A1 (en) | 2021-11-03 | 2022-11-03 | Anti-tau antibody compositions, dosage forms, and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005430A true MX2024005430A (es) | 2024-05-21 |
Family
ID=84360026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005430A MX2024005430A (es) | 2021-11-03 | 2022-11-03 | Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4426336A1 (https=) |
| JP (1) | JP2024540226A (https=) |
| KR (1) | KR20240118915A (https=) |
| AU (1) | AU2022381556A1 (https=) |
| CA (1) | CA3237660A1 (https=) |
| MX (1) | MX2024005430A (https=) |
| TW (1) | TW202334201A (https=) |
| WO (1) | WO2023079485A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025137359A1 (en) | 2023-12-20 | 2025-06-26 | Eisai R&D Management Co., Ltd. | Assay methods to identify a disease |
| CN117946264B (zh) * | 2024-03-21 | 2024-06-04 | 江西赛基生物技术有限公司 | 一种抗Tau蛋白单克隆抗体及其应用 |
| WO2026015877A1 (en) | 2024-07-12 | 2026-01-15 | Eisai R&D Management Co., Ltd. | Fluid biomarker |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3074420A2 (en) * | 2013-11-27 | 2016-10-05 | Ipierian, Inc. | Methods of treating a tauopathy |
| MA48595A (fr) * | 2016-12-07 | 2020-03-18 | Ac Immune Sa | Anticorps anti-tau et leurs méthodes d'utilisation |
| EP3697814A1 (en) | 2017-10-16 | 2020-08-26 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| US20240101654A1 (en) * | 2020-12-29 | 2024-03-28 | Neurimmune Ag | Human anti-tau antibodies |
-
2022
- 2022-11-03 TW TW111142044A patent/TW202334201A/zh unknown
- 2022-11-03 MX MX2024005430A patent/MX2024005430A/es unknown
- 2022-11-03 KR KR1020247018587A patent/KR20240118915A/ko active Pending
- 2022-11-03 JP JP2024525880A patent/JP2024540226A/ja active Pending
- 2022-11-03 AU AU2022381556A patent/AU2022381556A1/en active Pending
- 2022-11-03 WO PCT/IB2022/060604 patent/WO2023079485A1/en not_active Ceased
- 2022-11-03 EP EP22805963.0A patent/EP4426336A1/en active Pending
- 2022-11-03 CA CA3237660A patent/CA3237660A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022381556A1 (en) | 2024-05-02 |
| CA3237660A1 (en) | 2023-05-11 |
| EP4426336A1 (en) | 2024-09-11 |
| JP2024540226A (ja) | 2024-10-31 |
| KR20240118915A (ko) | 2024-08-05 |
| WO2023079485A1 (en) | 2023-05-11 |
| TW202334201A (zh) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024005430A (es) | Composiciones, formas farmaceuticas y metodos de anticuerpos anti-tau. | |
| EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
| WO2021044208A8 (en) | Antibody-drug conjugate comprising antibody against human ror1, and use for the same | |
| BR112021023024A2 (pt) | Anticorpo contra claudina 18a2 e uso do mesmo | |
| MX2018015393A (es) | Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo. | |
| MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
| EP4424324A3 (en) | Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis | |
| BR112016030686A2 (pt) | anticorpos anti tau humanizados | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| MX2020007406A (es) | Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo. | |
| ZA202103867B (en) | Tubulysins and protein-tubulysin conjugates | |
| MX2021009041A (es) | Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. | |
| PH12023550032A1 (en) | Tubulysins and protein-tubulysin conjugates | |
| JOP20220357A1 (ar) | ربط أجسام مضادة متعددة الخصوصية مع bcma | |
| MX2020010119A (es) | Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo. | |
| EA202191666A1 (ru) | Антитела к il-27 и их применение | |
| CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
| EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение | |
| JOP20230017A1 (ar) | أجسام مضادة لأميلويد بيتا | |
| PH12021552521A1 (en) | Aqueous pharmaceutical composition of an anti-il17a antibody and use thereof | |
| BR112023017556A2 (pt) | Anticorpo contra nkp46 e aplicação do mesmo | |
| BR112022004302A2 (pt) | Anticorpos anti-il-27 e usos dos mesmos | |
| MX2018007925A (es) | Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo. | |
| PH12022551810A1 (en) | Protein-antiviral compound conjugates |